← Back to Search

Monoclonal Antibodies

Treatment (atezolizumab, trabedersen) for Lung Cancer

Phase 2

Waitlist Available

Led By Rafael Santana-Davila

Research Sponsored by University of Washington

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 60 months

Awards & highlights

Study Summary

This trial tests a drug combo to treat metastatic/recurrent non-small cell lung cancer by blocking the growth & spread of tumor cells.

Eligible Conditions

Lung Cancer
Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 60 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 60 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective response rate

Secondary outcome measures

Disease control rate

Duration of response

Incidence of adverse events

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (atezolizumab, trabedersen)Experimental Treatment7 Interventions

Patients recieve atezolizumab IV on day 1 and trabedersen continuous IV on days 1-4 and days 15-19 of each cycle. Cycles repeat every 28 days for 104 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI during screening and every 8 weeks for the first 24 weeks and then every 12 weeks thereafter. Patients undergo blood sample collection prior to initiation of therapy, on day 4 of cycles 1-4, prior to weeks 4 and 8 of therapy, and at time of progression. Patients may also undergo biopsy during screening and/or 6-8 weeks after initiation of therapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Atezolizumab

2017

Completed Phase 3

~5860

Magnetic Resonance Imaging

2017

Completed Phase 3

~1190

Computed Tomography

2017

Completed Phase 2

~2720

Biospecimen Collection

2004

Completed Phase 2

~1730

Biopsy

2014

Completed Phase 4

~1090

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor

1,739 Previous Clinical Trials

1,847,928 Total Patients Enrolled

Oncotelic Therapeutics, Inc.UNKNOWN

Genentech, Inc.Industry Sponsor

1,539 Previous Clinical Trials

567,689 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA rendered a verdict regarding atezolizumab and trabedersen as viable treatments?

"While there is some evidence that Treatment (atezolizumab, trabedersen) may be safe to use, the lack of efficacy data means it receives a score of 2."

Answered by AI

Are there still opportunities to enroll in this experiment?

"The clinicaltrials.gov website reports that this trial is no longer looking to enrol new participants, as the entry was first published on December 1st 2023 and last updated on July 6th 2023. However, there are still 4221 alternate medical studies actively searching for volunteers at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

2023. "OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05935774.